MCP
VRTX icon

Miller Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Miller Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$141K Sell
283
-222
-44% -$98.4K 0.05% 130
2026
Q1 		$226K Hold
505
– – 0.11% 108
2025
Q4 		$229K Buy
+505
New +$218K 0.12% 109

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Miller Capital Partners's VRTX Position: Q2 2026 in Review

Miller Capital Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 44% in Q2 2026, selling an estimated $98.4K and leaving 283 shares worth $141K. The position accounts for 0.05% of the portfolio, ranked #130.

Miller Capital Partners first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $229K in Q4 2025. 1,744 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Miller Capital Partners held 283 shares of Vertex Pharmaceuticals worth $141K as of Q2 2026.
  • Miller Capital Partners sold 222 Vertex Pharmaceuticals shares in Q2 2026, an estimated $98.4K.
  • Vertex Pharmaceuticals made up 0.05% of Miller Capital Partners's portfolio in Q2 2026, its #130 holding.
  • Miller Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Miller Capital Partners's Vertex Pharmaceuticals position peaked at $229K in Q4 2025.
  • 1,744 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Miller Capital Partners's 13F filing for Q2 2026, filed 12 Aug 2026.